Arcus Q2 rev $26.8M, net loss $66.6M; ARC-8 PDAC data similar to historical chemo benchmarks; cash $1.27B

Arcus Biosciences, Inc.

Cash, cash equivalents and investments $1,271.1M at June 30, 2022, up from $681.3M at Dec 2021, driven by $725M Gilead payment.
Collaboration revenue $26.8M for Q2 2022 vs $9.5M YoY; net loss $66.6M vs $76.0M YoY.
ARC-8 interim analysis for quemliclustat in PDAC: data from randomized cohort similar to historical chemo benchmarks; Arcus and Gilead await mature data in 2023.
Four registrational Phase 3 trials of domvanalimab-based combinations ongoing or planned; ARC-7 topline disclosure expected H2 2022.
AB521 (HIF-2a inhibitor) Phase 1/1b to start Q3 2022; AB801 (AXL inhibitor) nominated; two new molecules expected in clinic in 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.